- Researchers at Osaka Metropolitan University have developed a new drug combination for relapsed/refractory acute myeloid leukemia (AML).
- The combination of venetoclax and azacitidine showed significant anti-cancer effects with mild toxicity in 12 AML patients who relapsed after hematopoietic cell transplantation.
- Venetoclax, an oral medication approved by the FDA, improved survival rates after one year for the treatment group compared to a control group.
- Immunological studies showed that venetoclax altered immune cells, enhancing anti-tumor activity in AML patients.
- The researchers hope this novel therapy will lead to the development of safer and more effective treatments for AML patients.
Source link
Oncology,Nephrology,Rheumatology